5th May 2016 08:42
LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Thursday said it has acquired exclusive global rights to a 250 millilitre bag form of foscarnet sodium from Medisol to boost the development of its Foscavir anti-viral treatment product.
Clinigen said it acquired the new bag presentation of the product, co-developed with Medisol, for an upfront payment, followed by milestone payments, though no further details on this were provided.
Clinigen has been supplying Foscavir to hospital in 250ml glass bottles since it acquired the product from blue-chip drugmaker AstraZeneca in 2010. It has been seeking to diversify how the Foscavir is presented to provide more options for hospital pharmacists.
"This further strengthens our portfolio and represents our commitment to revitalising our existing products in parallel to finding new products to add to our growing Specialty Pharma portfolio. Foscavir is a key product for the group and our success with the product has helped secure this exclusive development agreement for the bag form of Foscavir with Medisol," said Clinigen Chief Executive Peter George.
Clinigen shares were up 3.5% to 528.17 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L